ReWalk Personal Exoskeleton, a company dedicated to developing robotic technologies for individuals with lower limb disabilities, has secured $20.0 million in new funding. This investment round provides significant capital to support the company's ongoing operations and strategic objectives. ReWalk Personal Exoskeleton is known for its innovative ReWalk® Personal Exoskeleton, a device designed to offer patients with spinal cord injuries (SCI) a new level of independence through robotic-assisted walking.
The ReWalk Personal Exoskeleton enables users to participate in home-based functional ambulation programs, significantly elevating their health and quality of life. It stands out as the only personal exoskeleton engineered to navigate stairs and curbs, allowing users to experience the benefits of walking in various environments. The company's broader mission is to fundamentally change the quality of life for individuals with lower limb disability by creating and developing market-leading robotic technologies, including solutions for both spinal cord injury and stroke rehabilitation.
The $20.0 million in capital raised will be instrumental in advancing ReWalk Personal Exoskeleton's strategic growth plans. The company intends to deploy these funds to accelerate product development, expand its market presence, and enhance its operational capabilities. This funding round reflects investor confidence in the company's pioneering technology and its potential to make a substantial impact on the lives of individuals seeking greater mobility and independence.
With this new investment, ReWalk Personal Exoskeleton is poised to further its commitment to innovation in the field of medical robotics. The company plans to continue its efforts to expand access to its life-changing solutions, aiming to improve the health and quality of life for even more individuals with lower limb disabilities globally.
